There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

Roila F et al. Support Care Cancer 2019; 27: 1041. doi:10.1007/s00520-018-4393-9

Participants had disease that was resistant or intolerant to at least one available standard therapy or disease for which an investigational clinical trial is considered standard of care.

Treatment: Avelumab 10 mg/kg every 2 weeks plus best supportive care or best supportive care alone. https://clinicaltrials.gov/ct2/show/NCT02603432 Sponsor: Pfizer Reporting an interim analysis at the 2020 ASCO Annual Meeting , the investigators said that maintenance treatment with the PD-L1 inhibitor avelumab should be considered “a new standard of care” for patients who have not progressed after first-line platinum-based chemotherapy.

This was significantly higher than the rate of 52.2% observed among their 45 counterparts who instead received placebo plus best supportive care.

They believe that “these findings speak to an opportunity to better align the goals and values of patients from SGM groups with those of their oncologists through targeted education and culturally appropriate supportive care programs.”

The oral nonhormonal agent Q-122 appears to be an efficacious and well tolerated option for the control of vasomotor symptoms in women with breast cancer receiving adjuvant endocrine therapy, suggest phase 2 trial data.

“Because low-grade rashes are more frequently observed across targeted therapies, it is vital to ensure appropriate awareness of incidence rate and grade of cutaneous adverse events to counsel patients about these possibilities and to manage them with prophylactic, supportive care and active intervention when required.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.4327

Adjuvant treatment with atezolizumab is associated with a trend toward improved overall survival relative to best supportive care in people with resected stage II–IIIA non-small-cell lung cancer positive for PD-L1, indicate IMpower010 results.

Presenting the results in a poster at the ESMO Congress 2022 in Paris, France, the study authors said that “[t]hese first real-world data […] support the findings of the JAVELIN Bladder 100 trial,” which showed a significant improvement in survival with the addition of maintenance avelumab to best supportive care in this patient population and led to the approval of the PD-L1 inhibitor “in various countries worldwide.”

Related news content: Pembrolizumab no additional benefit for advanced UC   First-line pembrolizumab combination fails to boost advanced urothelial cancer survival (video) Maintenance immunotherapy JAVELIN Bladder 100 : Updated January 2023 Phase 3 Patient population: Locally advanced or metastatic urothelial cancer patients without progression after first-line platinum-based chemotherapy Treatments: Maintenance avelumab 10 mg/kg every 2 weeks plus best supportive care; or best supportive care alone https://clinicaltrials.gov/ct2/show/NCT02603432 Sponsor: Pfizer As reported in The New England Journal of Medicine in 2020, the JAVELIN Bladder 100 trial demonstrated a significant 31% reduction in the risk for death with the addition of maintenance avelumab to best supportive care (BSC) in this patient population.

Applying the EpiSwitch platform to peripheral blood samples from 496 participants of JAVELIN Bladder 100, collected before they were randomly assigned to receive maintenance avelumab plus best supportive care (BSC) or the latter alone, the team identified a chromatin loop that was strongly associated with low JAV-immuno scores.

The team concludes that “[t]he monitoring, diagnosis, and management of ILD/pneumonitis is an area of continuing improvement,” and refers clinicians to guidelines updated in 2019 on the dosing and supportive care required during T-DXd treatment. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Open 2022; doi:10.1016/j.esmoop.2022.100554

Previous studies have “reported on hearing loss associated with the administration of platinum compounds in patients undergoing active treatment for testicular or head and neck cancer,” but “extremely limited information is available on taxane-induced ototoxicity,” explain the study authors in BMJ Supportive & Palliative Care .

The recommendations encompass topics such as the diagnosis and treatment of early and advanced disease as well as supportive care and follow-up in young women with breast cancer, defined by the panel as women aged younger than 40 years at the time of diagnosis.

Interstitial lung disease/pneumonitis events were treated with a dose interruption or reduction, treatment discontinuation, corticosteroids, and supportive care.

The findings were presented in posters at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, and follow the primary analysis  showing a significant overall survival (OS) and progression-free survival (PFS) advantage with the addition of maintenance avelumab to best supportive care (BSC) in patients who had not progressed after four to six cycles of platinum-based chemotherapy.

The investigators point out, however, that “[a]lthough the main chemotherapy regimens are similar between [the] two groups, there are improvements in supportive care, imaging modalities, or radiotherapy in the study arm, as times of more than 10 years have passed since the historical control population was treated.”

In three clinical randomized trials, trilaciclib administration prior to standard-of-care chemotherapy for ES-SCLC reduced myelosuppression and the need for rescue interventions, improved patient-reported outcomes and the safety profile of the chemotherapy regimens, and had no impact on antitumor efficacy. s40267-021-00889-0 [Plain language summary] DOI [Teaser] Adis evaluation of trilaciclib (COSELA™) for the reduction of chemotherapy-induced myelosuppression in the management of ES-SCLC First intravenous CDK 4/6 inhibitor approved to decrease the incidence of chemotherapy-induced myelosuppression (CIM) in patients with ES-SCLC Administered prior to chemotherapy Provides multilineage myeloprotection, reducing the need for supportive care interventions and dose delays/reductions and hospitalizations related to CIM and sepsis Provides improvements in patient-reported outcomes Improves overall safety profile of chemotherapy regimens